Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
$0.00
$0.06
$9K1.0511,590 shs187 shs
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
$0.00
$0.00
$0.00
$3K0.212,733 shsN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
$0.00
$0.00
$0.00
$10KN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
$0.00
$0.00
$0.00
$7K-0.0726,442 shsN/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%-98.87%
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
0.00%0.00%0.00%0.00%0.00%
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
0.00%0.00%0.00%0.00%0.00%
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00%0.00%0.00%0.00%-83.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
N/AN/AN/AN/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
0.00
N/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
0.00
N/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/AN/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
$10K0.00N/AN/AN/ANaN
MusclePharm Co. stock logo
MSLP
MusclePharm
$50.04M0.00N/AN/A($0.94) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/A4/25/2025 (Estimated)
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
-$5.16MN/A0.00N/AN/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
-$12.87M-$0.58N/AN/AN/A-38.51%N/A-169.56%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
N/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
N/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/A
0.25
0.23

Institutional Ownership

CompanyInstitutional Ownership
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
N/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
N/A
MusclePharm Co. stock logo
MSLP
MusclePharm
15.49%

Insider Ownership

CompanyInsider Ownership
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
36.90%
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
10.30%
MusclePharm Co. stock logo
MSLP
MusclePharm
60.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
FluoroPharma Medical, Inc. stock logo
FPMI
FluoroPharma Medical
427.58 million17.40 millionNot Optionable
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
6143.88 million129.07 millionNot Optionable
MusclePharm Co. stock logo
MSLP
MusclePharm
2033.39 million13.12 millionNot Optionable

Recent News About These Companies

Editorial Podcasts
The No BS Guide to Building Lean Muscle
Stories about: muscle car
Top 6 Best Lean Muscle Supplements in 2024
The 5 best muscle rubs of 2024
10 Best Protein Powders Review
muscle sensor

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0005 0.00 (0.00%)
As of 09:30 AM Eastern

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

FluoroPharma Medical stock logo

FluoroPharma Medical OTCMKTS:FPMI

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

Global WholeHealth Partners stock logo

Global WholeHealth Partners OTCMKTS:GWHP

Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.

MusclePharm stock logo

MusclePharm OTCMKTS:MSLP

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.